Novartis获得Coartem Baby的核准,这是对4.5公斤以下婴儿的首例疟疾治疗。 Novartis gets approval for Coartem Baby, first malaria treatment for infants under 4.5 kg.

Novartis已经获得瑞士医疗中心的核准,这是对新生儿和年轻婴儿的首例疟疾治疗,即Coartem Baby。 Novartis has received approval for Coartem Baby, the first malaria treatment for newborns and young infants, from Swissmedic. 与疟疾新药研发公司(MMV)一起开发的这种可溶解的樱桃植物疗法解决了4.5公斤以下婴儿缺乏经核准的疟疾药物的问题。 Developed with Medicines for Malaria Venture (MMV), this dissolvable, cherry-flavored treatment addresses the lack of approved malaria medicines for infants under 4.5 kilograms. 该药物将主要在非营利基础上引进,预计8个非洲国家将迅速批准。 The drug will be introduced on a largely not-for-profit basis, with rapid approvals expected in eight African countries. 这一突破的目的是在疟疾流行地区,特别是非洲,增加获得治疗的机会。 This breakthrough aims to increase access to treatment in malaria-endemic regions, especially in Africa.